Neogenomics (NEO) Operating Expenses (2010 - 2026)

Neogenomics (NEO) has reported Operating Expenses for 17 consecutive years, with $99.1 million the latest figure, recorded in Q1 2026.

• Operating Expenses for Q1 2026 came in at $99.1 million, down 1.95% year-over-year; the trailing twelve-month figure through Mar 2026 was $428.2 million (up 10.58% YoY), and the FY2025 annual result was $430.2 million, up 12.55% from the prior year.
• Operating Expenses was $99.1 million for Q1 2026 at Neogenomics, up from $96.8 million in the prior quarter.
• Over five years, Operating Expenses peaked at $124.9 million in Q2 2025 and troughed at $83.2 million in Q4 2022.
• Average Operating Expenses over 5 years is $94.7 million, with a median of $94.4 million recorded in 2024.
• The widest YoY moves for Operating Expenses: up 59.24% in 2022, down 4.16% in 2022.
• Over 5 years, Operating Expenses stood at $83.2 million in 2022, then advanced by 3.55% to $86.2 million in 2023, then gained by 11.02% to $95.7 million in 2024, then increased by 1.15% to $96.8 million in 2025, then increased by 2.43% to $99.1 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $99.1 million in Q1 2026, $96.8 million in Q4 2025, and $107.5 million in Q3 2025.